Prot#CA209010: A Randomized, Blinded, Phase 2 Dose-Ranging Study of BMS-936558 (MDX-1106) in Subjects With Progressive Advanced/Metastatic Clear-Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy

Project: Research project

Project Details

StatusFinished
Effective start/end date6/21/11 → 6/30/20

Funding

  • Bristol-Myers Squibb Company (CA209010)